摘要
研究瓜拉纳对肥胖大鼠血浆脂类代谢物的影响,分析瓜拉纳改善肥胖脂代谢紊乱的作用机制。高脂饮食喂养建立肥胖大鼠模型,通过测量体质量、白色脂肪、肝脏质量、血脂含量,观察肝脏组织形态,评价瓜拉纳对肥胖大鼠的治疗效果;利用UHPLC-Q-TOF-MS脂质组学方法检测各组大鼠血浆样本脂类代谢物变化;Western blot法检测大鼠肝脏脂肪酸合酶、乙酰辅酶A羧化酶1、甘油三酯合成酶、肉碱棕榈酰转移酶Ⅰ、乙酰辅酶A酰基转移酶2蛋白表达。结果表明,瓜拉纳治疗显著减轻了高脂饮食诱导大鼠的体质量、白色脂肪和肝脏质量,缓解了血脂紊乱和肝脏脂肪变性;脂质组学结果显示,高脂模型组大鼠部分甘油三酯、磷脂显著升高,瓜拉纳治疗后部分甘油三酯和磷脂回调;Western blot结果显示,瓜拉纳抑制了肝脏脂肪酸与甘油三酯合成相关蛋白的表达,增加了脂肪酸β氧化相关蛋白的表达。甘油三酯和磷脂代谢异常是高脂饮食诱导大鼠的主要血浆脂代谢特征,瓜拉纳可能通过抑制肝脏脂肪酸与甘油三酯合成,增加脂肪酸β氧化调控部分甘油三酯和磷脂代谢,改善大鼠肥胖和脂代谢紊乱。
This study investigated the effect of guarana on plasma lipid metabolites in obese rats and analyzed its mechanism in the treatment of dyslipidemia in obesity.High-fat diet was used to establish obese rat models,and the therapeutic effect of guarana on obese rats was evaluated by measuring body weight,white fat,liver weight,and lipid content,as well as observing liver histomorphology.Lipid metabolites in plasma of rats in each group were detected by UHPLC-Q-TOF-MS lipidomics.The protein expressions of fatty acid synthase,acetyl-CoA carboxylase 1,triglyceride synthesis enzyme,carnitine palmitoyltransferaseⅠ,and acetyl-coenzyme A acyltransferase 2 in rat liver were detected using Western blot.The results revealed that guarana significantly reduced body weight,white fat,and liver weight of obese rats due to high-fat diet,and alleviated dyslipidemia and liver steatosis.Lipidomics showed that some triglycerides and phospholipids were significantly elevated in the high-fat model group,and part of them was reduced after guarana treatment.Western blot found that guarana inhibited the expression of hepatic fatty acid and triglyceride synthesis-related proteins and increased the expression of fatty acidβ-oxidation-related proteins.Abnormalities in triglyceride and phospholipid metabolism are the main characteristics of plasma lipid metabolism in obese rats induced by high-fat diet.Guarana may regulate partial triglyceride and phospholipid metabolism by inhibiting hepatic fatty acid and triglyceride synthesis and increasing fatty acidβ-oxidation,thereby improving rat obesity and dyslipidemia.
作者
梁敏雁
王松
徐子薇
王晶晶
胡小蝶
刘红宁
黄丽萍
LIANG Min-yan;WANG Song;XU Zi-wei;WANG Jing-jing;HU Xiao-die;LIU Hong-ning;HUANG Li-ping(School of Pharmacy,Jiangxi University of Chinese Medicine,Nanchang 330004,China;College of Pharmacy,Jinan University,Guangzhou 511436,China;Advanced Research Institute,Jiangxi University of Chinese Medicine,Nanchang 330004,China;Jiangxi Province Key Laboratory of Chinese Medicine Etiopathogenisis,Nanchang 330004,China;Jiangxi Provincial Key Laboratory of Traditional Chinese Medicine Pharmacology,Nanchang 330004,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2023年第14期3865-3873,共9页
China Journal of Chinese Materia Medica
基金
中央本级重大增减支项目(2060302-2101-11)
江西中医药大学校级科技创新团队发展计划项目(CXTD22007)。
